- Completed successful PK/PD study for otenaproxesul’s new formulation
- Phase II initiation on track for upcoming quarter
- Ended quarter with $28 million in cash and equivalents
.
- Study delivers data required for Phase II trial, on track to initiate next quarter- Confirms linear, dose-proportional pharmacokinetics- Complements strong safety data already reportedTORONTO (BUSINESS WIRE) $ATBPF Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leverag.